Biotech columnist Adam Feuerstein answers readers' questions about health care.
IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy but makes up for it by issuing a lot of promotional press releases.
After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.
Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.
There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a health care investor conference.
Mongersen is one of Celgene's most important pipeline drugs and a potential blockbuster treatment for Crohn's disease, an auto-immune disorder affecting the bowel.
Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.
The American Society of Clinical Oncology (ASCO) annual meeting will showcase new research into cancer immunotherapies.